MyeChild01 is an international randomised clinical trial with the primary aim of determining which of the current treatments combined with a novel drug will provide the best chance of survival for a a child with Acute Myeloid Leukaemia (AML). Gemtuzumab ozogamicin (GO) is a promising new drug whereby a chemotherapy drug is bound to an antibody targeting the cell surface marker CD33. This marker is present in 80% of AML cases, resulting in the chemotherapy drug being delivered directly to AML cells. The study is expected to run for 5-6 years with approximately 50 Australian patients enrolled each year.
|Effective start/end date||1/02/18 → 31/01/23|